Search

    When innovation and regulation
    move together


    Danny Van Roijen,     EU policy expert

    AI has enormous potential to transform drug development, from target discovery and clinical trials to pharmacovigilance. But that potential depends on one critical factor: trusted, usable data. In this session, Danny explores how evolving European regulations are helping create the conditions for responsible AI adoption. He'll discuss trusted data ecosystems, meaningful human oversight, quality-driven governance, and how regulators are building practical experience to support evidence-based AI in life sciences.

     

    In this session you will learn:

    • Where AI can add value across drug development, from target discovery to pharmacovigilance.
    • Why trusted, usable data is essential for responsible AI adoption.
    • How evolving European regulations are shaping data ecosystems and AI governance.
    • How meaningful human oversight and regulators’ practical experience support evidence-based AI.

    You’ll leave with a clear understanding of how trusted data, quality-driven governance, and European regulation can support responsible AI adoption in life sciences.